| Identification | Back Directory | [Name]
(S)-3-(2-aMino-3-MethylbutanaMido)propane-1-sulfonic acid | [CAS]
1034190-08-3 | [Synonyms]
ALZ-801
valiltramiprosate
ALZ-801;ALZ801;ALZ 801
Valiltramiprosate（ALZ-801）
NRZRFNYKMSAZBI-ZETCQYMHSA-N
(S)-3-(2-aMino-3-MethylbutanaMido)propane-1-sulfonic acid
3-[(2S)-2-amino-3-methylbutanamido]propane-1-sulfonic acid
1-Propanesulfonic acid, 3-[[(2S)-2-amino-3-methyl-1-oxobutyl]amino]-
β-amyloid peptide,Alzheimer,Amyloid-β,ALZ-801,Tramiprosate,disease,inhibit,Abeta,β-amyloid,ALZ801,Valiltramiprosate,Inhibitor,ALZ 801 | [Molecular Formula]
C8H18N2O4S | [MOL File]
1034190-08-3.mol | [Molecular Weight]
238.3 |
| Chemical Properties | Back Directory | [density ]
1.257±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Water:250.0(Max Conc. mg/mL);1049.1(Max Conc. mM) | [form ]
Solid | [pka]
1?+-.0.50(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water : 250 mg/mL (1049.10 mM; Need ultrasonic) |
| Hazard Information | Back Directory | [Uses]
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease[2]. | [in vivo]
ALZ-801 (oral administration; 172?mg/kg; single dose) exhibits mean AUCt values of 58,758 and? 5841 ng/ml.h in plasma and brain, respectively. The ALZ-801: Tramiprosate ratio in plasma and brain is 1.8 and 3.1, respectively in male CD-1 mice[1]. | [storage]
Store at -20°C | [References]
[1] John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861.
[2] Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. DOI:10.1007/s40262-017-0608-3 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Shanghai URChem Limited
|
| Tel: |
+86-021-50890968，021-50891159 +86-18601776121 |
| Website: |
http://www.urchem.com |
|